The Nonmelanoma Skin Cancer market is expected to experience substantial growth from 2024 to 2034, driven by increasing ...

Regeneron’s Eylea franchise remains resilient despite biosimilar competition. Read what makes REGN stock a Strong Buy despite ...

Meredith McKean, MD, MPH, discusses the background and goals from the recent long-term follow-up of a phase 1 study evaluating the combination of fianlimab and cemiplimab in advanced melanoma.

Along with first-line PDL1-positive NSCLC, Libtayo is also used to treat two forms of skin cancer – cutaneous squamous cell carcinoma and basal cell carcinoma. Merck claims adjuvant win in ...

Libtayo was a late entrant into the PD-1/PD-L1 inhibitor market and while it has been able to carve out a small niche in cutaneous squamous cell carcinoma (CSCC), another form of skin cancer ...

Merck’s Keytruda (pembrolizumab) and American biotech Regeneron Pharmaceuticals’ Libtayo (cemiplimab), have been on the ... advanced cutaneous squamous cell carcinoma, a type of skin cancer, in ...

While skin cancer rates are growing in many parts of the world, experts disagree on whether this represents a true epidemic or overdiagnosis is a contributing factor.

Patients with a rare disease called mucous membrane pemphigoid are at risk of developing squamous cell carcinoma and basal cell carcinoma, finds a new study.

Researchers from the Agency for Science, Technology and Research (A*STAR) and the National Healthcare Group (NHG) have ...